Our directory is intended as a resource for people with peanut and nut allergies. It contains foods, helpful products, and much more.
- What is a Peanut Allergy
- Foods to Avoid
- The Allergic Reaction
- Recognizing and Treating Anaphylaxis
- Epinephrine Auto-Injectors
- Medical ID Bracelets
- Support Groups
Peanut Free and Nut Free
Other Food Allergies
This was in Tanox\'s quarterly report
In May 2002, we completed a double blind, placebo controlled Phase 2 clinical trial in TNX-901 to evaluate its safety and efficacy in patients with severe peanut allergy. TNX-901 is a humanized anti-IgE monoclonal antibody distinct from Xolair. The trial involved 84 patients in 4 dose groups, (0, 150, 300, and 450 mg). The primary endpoint, based on an increase in symptom threshold to peanuts by oral food challenge, was met with statistical significance. Following receipt of a ruling from an arbitration panel that Tanox does not have the right to independently develop TNX-901, Tanox has suspended its plans to further develop the drug independently (See Note 8).
In October 2002 it was ruled that Tanox has to collaboratively develop this drug with Genentech. Does anyone have information about Genentech's intention of pursuing Phase III clinical trials?